Matthew Kohler to Cost-Benefit Analysis
This is a "connection" page, showing publications Matthew Kohler has written about Cost-Benefit Analysis.
Connection Strength
0.085
-
Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer. Cancer. 2012 Jan 15; 118(2):386-91.
Score: 0.085